© Copyright Acquisition International 2025 - All Rights Reserved.

Article Image - Evotec Announces Its Intent to Acquire Cyprotex Plc
Posted 26th October 2016

Evotec Announces Its Intent to Acquire Cyprotex Plc

Acquisition would add world-leading high-quality ADME-Tox services and strengthen Evotec's leadership in drug discovery

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Evotec Announces Its Intent to Acquire Cyprotex Plc
Image

Evotec Announces Its Intent to Acquire Cyprotex Plc

Acquisition would add world-leading high-quality ADME-Tox services and strengthen Evotec’s leadership in drug discovery

– Evotec will pay approximately £ 55.36 m (EUR 62.00 m) in cash for the full share capital of Cyprotex and funding of all existing debt of the AIM-listed company

– Proposed acquisition, unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has made an offer to acquire Cyprotex PLC (“Cyprotex”, AIM: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK. Cyprotex serves the industry’s increasing requirement for earlier drug screening, regulatory requirements and reducing the reliance on animal testing.

The proposed acquisition, which has been unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016. Evotec will pay approximately £ 55.36 m (EUR 62.00 m; £/EUR exchange rate of 1.12) in cash for the acquisition of all 26.1 million issued and to be issued Cyprotex shares and the funding of all existing company debt. The offer of 1.60 £ per Cyprotex share reflects a 9.4% premium to the VWAP of the past 30 trading days at AIM. The offer is intended to be implemented by a scheme of arrangement regulated by the UK takeover code, with already >50% shares secured irrevocable. The acquisition will add to Evotec’s revenues and be accretive to Evotec’s 2017 EBITDA.

Cyprotex is the world’s largest contract research organisation specialising in pre-clinical ADME-Tox and DMPK serving the Pharmaceutical, Chemical, Agrochemical and Cosmetics markets. Cyprotex, headquartered in the UK, was founded in 1999 and is publicly traded on AIM (CRX). It has 136 employees working from sites at Macclesfield and Alderley Park, both of which are located near Manchester in the UK, and at Watertown, MA, and Kalamazoo, MI, in the USA. With more than 1,500 partners, Cyprotex has a very strong customer network. Cyprotex reported H1 2016 revenues of £ 8.73 m (EUR 9.78 m) (H1 2015: £ 6.93 m (EUR 7.76 m)) with an underlying EBITDA of £ 2.34 m (EUR 2.62 m) (H1 2015: £ 1.10 m (EUR 1.23 m)).

Sharpening Evotec’s leadership role in drug discovery The acquisition strengthens Evotec’s high-end drug discovery platform and capabilities with access to the market’s most industrialised ADME-Tox platform and proven expertise in in vitro ADME screening, mechanistic and high-content toxicology screening and predictive modelling.

This perfectly augments Evotec’s drive for innovation efficiency in drug discovery by enabling its partners to make early informed decisions on a molecule’s suitability for further development. The Cyprotex platform can be leveraged in a high-throughput manner or to support integrated drug discovery projects.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “The ability to test or predict a molecule’s suitability as a drug at an early stage is critical in the drive to increase the efficiency of drug discovery.

The proposed acquisition of Cyprotex is a completely logical step to strengthen Evotec’s position as the world’s leading partner of choice for driving such efficiencies in drug discovery to the industry. The proven technology platform of Cyprotex and its expert and dedicated employees will be a strong addition to our best-in-class drug discovery platform and resources. We also expect that both organisations will leverage their extensive partner networks to identify further commercial synergies.”

Dr Werner Lanthaler, Chief Executive Officer of Evotec, added: “Our focus to make the most innovative and capital efficient drug discovery platform will be perfectly extended by Cyprotex. Given our strong performance over the last years, a very good outlook of our business into the coming years, and the commercial profile of Cyprotex we also feel very comfortable in using the cash on our strong balance sheet for this accretive acquisition. We are very much looking forward to welcoming the employees of Cyprotex within the Evotec Group after closing of the transaction.”

Categories: Innovation, Leadership


You Might Also Like
Read Full PostRead - Eye Icon
Giving A Personal Touch to Clinical Trials
Innovation
01/03/2018Giving A Personal Touch to Clinical Trials

GlobalCare Clinical Trials brings over 100 years of experience in the clinical trials and home healthcare industries supporting over 400 studies in over 50 countries by effectively delivering high quality and convenient clinical trial services in the home or a

Read Full PostRead - Eye Icon
6 Forms of Technology That Are Streamlining Healthcare Provision in 2023 and Beyond
Innovation
24/05/20236 Forms of Technology That Are Streamlining Healthcare Provision in 2023 and Beyond

The healthcare industry is experiencing a major transformation with the introduction of new technologies. New technology is changing how we access and deliver healthcare services, from electronic health records to telemedicine.

Read Full PostRead - Eye Icon
Capital Croissance Acquisition of Minority Stake in Altima
M&A
03/08/2015Capital Croissance Acquisition of Minority Stake in Altima

Capital Croissance Acquisition of Minority Stake in Altima

Read Full PostRead - Eye Icon
Tips from a Peachtree Corners Personal Injury Attorney
News
16/11/2023Tips from a Peachtree Corners Personal Injury Attorney

After a personal injury, securing fair compensation may seem like an overwhelming task. The decisions you make now can have an impact on your future, and you will want to be sure you receive the maximum amount for your damages. In a car accident, slip and fall

Read Full PostRead - Eye Icon
A Long and Strong Presence
Innovation
11/09/2017A Long and Strong Presence

A Long and Strong Presence

Read Full PostRead - Eye Icon
Polaris Acquires Timbersled
M&A
23/04/2015Polaris Acquires Timbersled

Polaris Industries Inc. today announced the acquisition of Timbersled Products, Inc.

Read Full PostRead - Eye Icon
A Full Service Offering
Legal
01/12/2016A Full Service Offering

For more than 20 years, the Emmanuel Jacques Almosnino (EJA) law firmbased on the luxurious island of Saint Barth- has effectively represented VIPs and high-net worth clients from around the world.

Read Full PostRead - Eye Icon
3 Tax Tips for Non-Profits
Finance
20/04/20213 Tax Tips for Non-Profits

The UK government allows charities, aka non-profits, to use quite a few tax exemptions and benefits to minimise their total due tax amount every year. However, in order to really take advantage of those benefits as a non-profit organisation, the administrative

Read Full PostRead - Eye Icon
5 ways that SMEs can overcome cash flow challenges in uncertain markets
News
01/11/20245 ways that SMEs can overcome cash flow challenges in uncertain markets

Across the UK, many small and medium-sized enterprises (SMEs) face financial pressures due to a variety of factors, including fluctuating economic conditions and rising operational costs. These challenges often leave business owners searching for reliable stra



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have 14 unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow